Central Surgical Association| Volume 142, ISSUE 4, P529-537, October 2007

Download started.


Outcomes after pancreatectomy for intraductal papillary mucinous neoplasms of the pancreas: An institutional experience


      To evaluate the experience with pancreatectomy for intraductal papillary mucinous neoplasm (IPMN) at a single academic institution.


      A prospective pancreatic database was reviewed and identified 43 patients with IPMN who were managed operatively. Clinicopathologic features and predictors of outcome were examined. The World Health Organization pathologic classification of IPMN was utilized.


      IPMN was diagnosed in 21% of patients who underwent pancreatic resection for solid or cystic mass lesions. Ninety-five percent of patients were symptomatic. Patients were managed with total pancreatectomy, pancreaticoduodenectomy, distal pancreatectomy, central pancreatectomy, or enucleation. Nine patients had adenomas, 14 had borderline neoplasms, 10 had carcinoma in situ, and 9 had invasive carcinoma. Overall, 23 patients (53%) had lesions with main duct involvement. Frozen section transection margins were positive for malignancy in 2 patients. With a mean follow-up of 17 months, the 5-year disease-specific survival for patients with main duct involvement was 67%. The 5-year disease-specific survival for patients with benign lesions was 100%, and 61% for patients with malignant lesions (P = .02). The presence of symptoms, increased CA 19-9, and tumor size were not predictive of malignancy. Increased serum bilirubin concentrations were predictive of malignancy (P = .03). Main duct involvement was also associated with malignancy (P < .02).


      Cancer is found in 65% of patients with IMPN involving the main duct. Based on our data, patients with symptomatic, main duct involvement, especially those with an increased serum bilirubin, should be offered resection. Alternatively, patients with side branch IPMN may be managed conservatively.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Longnecker D.S.
        • Adler G.
        • Hruban R.H.
        • Kloppel G.
        Intraductal papillary-mucinous neoplasms of the pancreas.
        in: Hamilton S.R. Aaltonen L.A. World Health Organization Classification of Tumours: Tumours of the Digestive System. IARC Press, Lyon, France2000: 237-240
        • Chari S.T.
        • Yadav D.
        • Smyrk T.C.
        • et al.
        Study of recurrence after surgical resection of intraductal papillary mucinous neoplasm of the pancreas.
        Gastroenterology. 2002; 123: 1500-1507
        • D’Angelica M.
        • Brennan M.F.
        • Suriawinata A.A.
        • Klimstra D.
        • Conlon K.C.
        Intraductal papillary mucinous neoplasms of the pancreas: an analysis of clinicopathologic features and outcome.
        Ann Surg. 2004; 239: 400-408
        • Raut C.P.
        • Cleary K.R.
        • Staerkel G.A.
        • et al.
        Intraductal papillary mucinous neoplasms of the pancreas: effect of invasion and pancreatic margin status on recurrence and survival.
        Ann Surg Oncol. 2006; 13: 582-594
        • Salvia R.
        • Fernández-del Castillo C.
        • Bassi C.
        • et al.
        Main-duct intraductal papillary mucinous neoplasms of the pancreas: clinical predictors of malignancy and long-term survival following resection.
        Ann Surg. 2004; 239: 678-685
        • Sohn T.A.
        • Yeo C.J.
        • Cameron J.L.
        • et al.
        Intraductal papillary mucinous neoplasms of the pancreas: an updated experience.
        Ann Surg. 2004; 239: 788-797
        • Wada K.
        • Kozarek R.A.
        • Traverso L.W.
        Outcomes following resection of invasive and noninvasive intraductal papillary mucinous neoplasms of the pancreas.
        Am J Surg. 2005; 189: 632-636
        • Doi R.
        • Fujimoto K.
        • Wada M.
        • Imamura M.
        Surgical management of intraductal papillary mucinous tumor of the pancreas.
        Surgery. 2002; 132: 80-85
        • Salvia R.
        • Bassi C.
        • Falconi M.
        • et al.
        Intraductal papillary mucinous tumors of the pancreas.
        JOP. 2005; 6: 112-117
        • Tanaka M.
        • Chari S.
        • Adsay V.
        • et al.
        International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas.
        Pancreatology. 2006; 6: 17-32
        • Kaplan E.
        • Meier P.
        Non-parametric estimation from incomplete observations.
        J Am Stat Assoc. 1958; 53: 457-481
        • Wiesenauer C.A.
        • Schmidt C.M.
        • Cummings O.W.
        • et al.
        Preoperative predictors of malignancy in pancreatic intraductal papillary mucinous neoplasms.
        Arch Surg. 2003; 138: 610-617
        • Fernández-del Castillo C.
        • Targarona J.
        • Thayer S.P.
        • Rattner D.W.
        • Brugge W.R.
        • Warshaw A.L.
        Incidental pancreatic cysts: clinicopathologic characteristics and comparison with symptomatic patients.
        Arch Surg. 2003; 138 (427-23)
        • White R.
        • D’Angelica M.
        • Katabi N.
        • et al.
        Fate of the remnant pancreas after resection of noninvasive intraductal papillary mucinous neoplasm.
        J Am Coll Surg. 2007; 204: 987-993